Belite Bio Investor Relations Material
Latest events
Q4 2024
Belite Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Belite Bio Inc
Access all reports
Belite Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics targeting retinal degenerative eye diseases and certain metabolic diseases. The company's primary focus includes conditions such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease type 1 (STGD1), which can lead to permanent blindness. Additionally, Belite Bio is exploring treatments for metabolic disorders like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Belite Bio, Inc. was founded in 2016 and is headquartered in San Diego, California. The company's shares are listed on the NASDAQ.
Key slides for Belite Bio Inc
Q2 2024
Belite Bio Inc
Q4 2024
Belite Bio Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
BLTE
Country
🇺🇸 United States